Research News for 2010
-
Experimental Regimen May Work Against Treatment-Resistant Breast Cancer
A combination of two experimental targeted therapies shows promise in treating advanced-stage HER2-positive breast cancer.
-
Radioactive Tag on Herceptin May Allow Doctors to Track Effectiveness
Attaching a radioactive tag to the targeted therapy Herceptin might allow researchers to monitor how HER2-positive breast cancer cells respond to Herceptin treatment.
-
Avastin-Abraxane Combo May Treat Triple-Negative Breast Cancer
Research in mice suggests that Avastin combined with Abraxane works better against triple-negative breast cancer cells than Abraxane alone.
-
Tamoxifen and Evista Both Good Choices to Reduce Risk
Both tamoxifen and Evista lower the risk of invasive and non-invasive breast cancer in women at high risk, and each medicine has benefits and risks.
-
Too Much MicroRNA Linked to Herceptin Resistance
New research suggests that too much microRNA-21 in HER2-positive breast cancer cells is linked to Herceptin resistance.
-
Herceptin May Destroy Cancer Stem Cells
Preliminary research using math formulas suggests that HER2-negative breast cancers may benefit from Herceptin.
-
Tykerb May Treat Herceptin-Resistant HER2-Positive Breast Cancer
Research on cells suggests that HER2-positive breast cancers resistant to Herceptin may respond to Tykerb.
-
Overactive HOTAIR Gene Makes Breast Cancer More Likely to Metastasize
New research has found that breast cancers with an overactive HOTAIR (HOX antisense intergenic RNA) gene are more likely to spread to parts of the body away from the breast (metastasize).
-
Drinking Alcohol at Young Age Linked to Benign Breast Disease
A new study suggests that teens and young women who regularly drink alcohol seem to have a higher risk of being diagnosed with benign breast disease compared to young women who don't regularly drink.
-
Diagnosed Women with Abnormal Breast Cancer Gene Have Higher Risk of New Cancer in Opposite Breast
Research suggests that women with an abnormal BRCA1 or BRCA2 gene who have been diagnosed with breast cancer are 4 times more likely to be diagnosed with a new cancer in the opposite breast compared to women without an abnormal breast cancer gene diagnosed with breast cancer.
